<ARTICLE> 5 <LEGEND> This schedule contains summary financial information extracted from the unaudited consolidated financial statements of PathoGenesis Corporation for the three months ended March 31, 1998, and is qualified in its entirety by reference to such financial statements. </LEGEND> <PERIOD-TYPE> 3-MOS <FISCAL-YEAR-END> DEC-31-1998 <PERIOD-START> JAN-01-1998 <PERIOD-END> MAR-31-1998 <CASH> 1,467,265 <SECURITIES> 66,313,271 <RECEIVABLES> 11,318,597 <ALLOWANCES> 0<F1> <INVENTORY> 6,070,696 <CURRENT-ASSETS> 86,291,267 <PP&E> 18,083,173 <DEPRECIATION> 7,759,331 <TOTAL-ASSETS> 97,403,523 <CURRENT-LIABILITIES> 6,683,692 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 16,246 <OTHER-SE> 191,707,694 <TOTAL-LIABILITY-AND-EQUITY> 97,403,523 <SALES> 14,527,031 <TOTAL-REVENUES> 14,664,897 <CGS> 2,669,816 <TOTAL-COSTS> 14,778,450 <OTHER-EXPENSES> 33,500 <LOSS-PROVISION> 0<F2> <INTEREST-EXPENSE> 0 <INCOME-PRETAX> 984,590 <INCOME-TAX> 0 <INCOME-CONTINUING> 984,590 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 984,590 <EPS-PRIMARY> .06 <EPS-DILUTED> .06 <FN> <F1> The amount of receivables reported is net of $1,317,068 of allowances. <F2> The total costs include loss provision of $100,000. </FN>